Orris

Non resolving pneumonia Give me full A2 style detailed answer with all introduction all etiology all pathology all pathophysiology all classification all pathogenesis all clinical features all diagnosis all treatment all hrct findings and drug with doses newer therapy from fishman and ers guidelines

Reading File
Finding Sources
Finding Sources
Reading File
I found the main Fishman section on non-resolving pneumonia. Let me read those specific lines and also search for HRCT and treatment content in parallel.
Reading File
Finding Sources
Good — I found the Fishman section. Now let me read the full non-resolving pneumonia chapter content from Fishman and also pull from Murray & Nadel and Goldman-Cecil simultaneously.
general-purpose

You are a medical research subagent. Your task is to search the medical library database and read textbook content about "non-resolving pneumonia" from Fishman's Pulmonary Diseases and Disorders. STEP 1: Query the database to find all sections in Fishman's book about non-resolving pneumonia: ```sql SELECT title, book_title, '/textbooks/' || block_file_path AS file_path, line_number, para_line_ranges, para_count FROM headings_fts WHERE headings_fts MATCH 'pneumonia' AND book_title LIKE '%Fishman%' ORDER BY rank LIMIT 20 ``` STEP 2: Read the file /textbooks/9781260473940/9781260473940_block7.md starting at offset 3220 with limit 100. STEP 3: Search for the dedicated non-resolving pneumonia chapter in Fishman using: ```sql SELECT title, book_title, '/textbooks/' || block_file_path AS file_path, line_number, para_line_ranges, para_count FROM headings_fts WHERE headings_fts MATCH 'Nonresolving' ORDER BY rank LIMIT 10 ``` STEP 4: Search ALL blocks in Fishman for the dedicated chapter on non-resolving pneumonia: ```sql SELECT title, book_isbn, '/textbooks/' || block_file_path AS file_path, line_number FROM headings_fts WHERE headings_fts MATCH 'pneumonia' AND book_title LIKE '%Fishman%' ORDER BY rank LIMIT 20 ``` STEP 5: Search paragraphs for the non-resolving pneumonia content including etiology, pathophysiology, classification, diagnosis, treatment: ```sql SELECT book_title, section_heading, '/textbooks/' || block_file_path AS file_path, line_start, line_end, snippet(paragraphs_fts, 0, '>>>', '<<<', '...', 50) as snippet FROM paragraphs_fts WHERE paragraphs_fts MATCH '"nonresolving" OR "non-resolving" AND (etiology OR pathology OR treatment OR diagnosis OR classification)' ORDER BY rank LIMIT 20 ``` STEP 6: Read several blocks from Fishman's book. Try reading: - /textbooks/9781260473940/9781260473940_block7.md from offset 3226 to 3500 - Also search for block files that might contain the main pneumonia chapter STEP 7: Search for the main pneumonia chapter in Fishman which likely has the most comprehensive coverage: ```sql SELECT b.id, b.book_isbn, b.block_number, b.file_path, h.title, h.line_number FROM blocks b JOIN headings h ON h.block_id = b.id WHERE b.book_isbn = '9781260473940' AND h.title LIKE '%pneumonia%' ORDER BY h.line_number LIMIT 20 ``` STEP 8: Read the Fishman book overview to understand block structure: ```sql SELECT * FROM v_book_overview WHERE isbn = '9781260473940' ``` STEP 9: Look at table of contents for Fishman around the pneumonia chapters: ```sql SELECT speciality, book_title, book_isbn, level, heading, block_number, block_file_path, line_number FROM v_toc WHERE book_isbn = '9781260473940' AND heading LIKE '%pneumonia%' OR heading LIKE '%Pneumonia%' ORDER BY line_number LIMIT 30 ``` STEP 10: Find and read the dedicated non-resolving pneumonia chapter. This is a comprehensive chapter in Fishman - search all blocks: ```sql SELECT speciality, book_title, book_isbn, level, heading, block_number, block_file_path, line_number FROM v_toc WHERE book_isbn = '9781260473940' ORDER BY block_number, line_number LIMIT 20 OFFSET 200 ``` After finding the correct block file and line number for the non-resolving pneumonia dedicated chapter (not just the bronchoscopy section), read 700 lines from that location. Return ALL the raw text content you found about non-resolving pneumonia including: definition, etiology, pathophysiology, classification, clinical features, diagnosis, treatment, HRCT findings. Quote directly from the textbook.

Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
Reading File
general-purpose

You are a medical research subagent. Read the main non-resolving/failure of therapy section from Fishman's Pulmonary Diseases textbook. STEP 1: Read the file /textbooks/9781260473940/9781260473940_block25.md starting at offset=1700 with limit=700. This should contain the "FAILURE OF THERAPY" section about non-resolving pneumonia. STEP 2: Then read from offset=2400 with limit=700. STEP 3: Then read from offset=3100 with limit=700. STEP 4: Also search for HRCT patterns in pneumonia using: ```sql SELECT book_title, section_heading, '/textbooks/' || block_file_path AS file_path, line_start, line_end, snippet(paragraphs_fts, 0, '>>>', '<<<', '...', 50) as snippet FROM paragraphs_fts WHERE paragraphs_fts MATCH 'pneumonia AND (HRCT OR "high-resolution CT") AND (consolidation OR "ground glass" OR bronchogram)' ORDER BY rank LIMIT 10 ``` STEP 5: Search for treatment of non-resolving pneumonia and antibiotic doses: ```sql SELECT book_title, section_heading, '/textbooks/' || block_file_path AS file_path, line_start, line_end, snippet(paragraphs_fts, 0, '>>>', '<<<', '...', 50) as snippet FROM paragraphs_fts WHERE paragraphs_fts MATCH '(antibiotic OR treatment) AND pneumonia AND (failure OR nonresolving OR "non-resolving")' ORDER BY rank LIMIT 10 ``` STEP 6: Search for organizing pneumonia HRCT and treatment: ```sql SELECT book_title, section_heading, '/textbooks/' || block_file_path AS file_path, line_start, line_end, snippet(paragraphs_fts, 0, '>>>', '<<<', '...', 50) as snippet FROM paragraphs_fts WHERE paragraphs_fts MATCH '"organizing pneumonia" AND (HRCT OR "high resolution CT" OR treatment OR corticosteroid)' ORDER BY rank LIMIT 10 ``` STEP 7: Find and read the ERS guidelines or CAP treatment failure sections from Murray & Nadel: ```sql SELECT title, book_title, '/textbooks/' || block_file_path AS file_path, line_number, para_line_ranges, para_count FROM headings_fts WHERE headings_fts MATCH 'treatment failure pneumonia' ORDER BY rank LIMIT 10 ``` Return all the raw extracted text content verbatim from each step. Focus particularly on: etiology of non-resolving pneumonia, pathophysiology, classification, clinical features, HRCT findings, treatment protocols with drug doses, newer therapies.

Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
Finding Sources
Reading File
Reading File
Now I have all the source material needed. Let me compile the comprehensive A2-style answer.

NON-RESOLVING PNEUMONIA

A Comprehensive Review

1. INTRODUCTION

Non-resolving pneumonia (NRP) is defined as a pneumonia that fails to respond to initial antibiotic therapy or fails to show expected radiographic clearance within a defined time frame. It represents a clinical challenge because it forces the physician to reconsider whether the diagnosis is truly pneumonia, whether the pathogen is treated correctly, or whether a completely different disease process is at play.
Standard definition (Fishman's Pulmonary Diseases):
"Non-resolving pneumonia is defined as a lack of improvement or worsening of symptoms despite a minimum of 10 days of antibiotic therapy, or failure of radiographic abnormalities to resolve after 2 to 3 months." — Fishman's Pulmonary Diseases and Disorders
Murray & Nadel's recognizes two temporal patterns:
  • Progressive pneumonia: worsening within 72 hours of initiating appropriate antibiotic therapy
  • Nonresponding (slowly resolving) pneumonia: failure to improve by day 5–7, or failure of radiographic resolution within the expected time (up to 6–8 weeks in elderly/comorbid patients)
Expected time to radiographic resolution varies by organism and host:
Pathogen/HostTime to Resolution
Streptococcus pneumoniae (young, healthy)2–4 weeks
Legionella pneumophila6–12 weeks
Gram-negative enteric bacilli6–10 weeks
Pneumocystis jirovecii4–6 weeks
Mycobacterium tuberculosisMonths
Elderly / comorbid hostUp to 12 weeks

2. ETIOLOGY

Causes are broadly classified into infectious and non-infectious categories. Fishman's describes these as: inadequate antibiotic therapy, resistant or highly virulent organisms, impaired host defenses, obstructing endobronchial lesions, or a noninfectious cause.

A. Infectious Causes (~40% of cases)

i. Inappropriate/Inadequate Initial Therapy

  • Wrong antibiotic choice (failure to cover atypical pathogens, anaerobes, MRSA, Pseudomonas)
  • Poor lung penetration: aminoglycosides and daptomycin are inactivated by pulmonary surfactant — a critical pharmacological point
  • Inadequate dosing or duration
  • Failure to use combination therapy when needed (e.g., Legionella)

ii. Resistant Organisms

  • Streptococcus pneumoniae: Penicillin-resistant strains (PRSP), fluoroquinolone-resistant strains
  • Staphylococcus aureus: MRSA — requires vancomycin, linezolid, or ceftaroline
  • Haemophilus influenzae: β-lactamase producing strains
  • Pseudomonas aeruginosa: Multi-drug resistant (MDR-Pseudomonas) — common in structural lung disease (bronchiectasis, cystic fibrosis)
  • Klebsiella pneumoniae: Extended-spectrum β-lactamase (ESBL) producers, carbapenem-resistant strains

iii. Unusual/Uncommon Pathogens Not Initially Suspected

  • Mycobacterium tuberculosis and non-tuberculous mycobacteria (NTM)
  • Endemic fungi: Histoplasma capsulatum, Blastomyces dermatitidis, Coccidioides immitis
  • Opportunistic fungi: Aspergillus fumigatus, Mucorales (mucormycosis), Pneumocystis jirovecii
  • Nocardia asteroides
  • Actinomyces israelii
  • Anaerobes (especially in aspiration)
  • Atypical bacteria not covered: Legionella spp. (if β-lactam-only therapy), Chlamydophila psittaci, Coxiella burnetii (Q fever)
  • Viruses: Influenza (especially with bacterial co-infection), CMV (in immunocompromised), adenovirus

iv. Local/Structural Complications

  • Parapneumonic effusion / Empyema: Loculated empyema prevents antibiotic penetration
  • Lung abscess formation: requires prolonged therapy or drainage
  • Obstructing endobronchial lesion: causing postobstructive pneumonia (see differential)
  • Septic emboli: right-sided endocarditis (Staphylococcus), IV drug use, infected venous catheter

v. Impaired Host Defenses (Immunocompromised Host)

  • HIV/AIDS (CD4 <200: PCP, CMV, MAC, disseminated fungal)
  • Hematologic malignancy, prolonged neutropenia
  • Solid organ / bone marrow transplant recipients
  • Corticosteroid therapy (>20 mg prednisone/day equivalent)
  • Hypogammaglobulinemia
  • Bronchiectasis, cystic fibrosis, ciliary dyskinesia (impaired mucociliary clearance)
  • Diabetes mellitus, chronic alcohol use, cirrhosis

B. Non-Infectious Causes (~22–40% of cases — "Mimics of Pneumonia")

This is one of the most critical aspects of NRP evaluation. Fishman's (Table 122-10) lists over 30 non-infectious mimics:
I. Inflammatory/Immune Lung Disease
  • Cryptogenic Organizing Pneumonia (COP) — formerly BOOP: most important mimic; bilateral peripheral consolidation that does not respond to antibiotics
  • Acute Eosinophilic Pneumonia (AEP) and Chronic Eosinophilic Pneumonia (CEP)
  • Hypersensitivity Pneumonitis (HP) — farmer's lung, bird fancier's lung
  • Sarcoidosis — alveolar pattern
  • Eosinophilic Granulomatosis with Polyangiitis (EGPA) (Churg-Strauss)
  • Granulomatosis with Polyangiitis (GPA) (Wegener's)
  • Diffuse Alveolar Hemorrhage (DAH): Goodpasture's, SLE, vasculitis
  • Drug-induced pneumonitis: methotrexate, amiodarone, nitrofurantoin, bleomycin, checkpoint inhibitors
  • Radiation pneumonitis
  • Aspiration pneumonitis (chemical, non-infectious)
II. Neoplasms
  • Bronchogenic carcinoma (especially adenocarcinoma presenting as consolidation)
  • Bronchoalveolar carcinoma / Adenocarcinoma in situ
  • Pulmonary lymphoma: Primary pulmonary lymphoma (MALT)
  • Lymphomatoid granulomatosis
  • Pulmonary carcinoid tumors (causing postobstructive pneumonia)
  • Metastatic disease to lung
III. Vascular Causes
  • Pulmonary embolism with infarction — pulmonary infarct mimics consolidation
  • Pulmonary vasculitis
IV. Other Causes
  • Lipoid pneumonia (mineral oil aspiration, fat embolism)
  • Pulmonary alveolar proteinosis (PAP)
  • Transfusion-related acute lung injury (TRALI)
  • Congestive heart failure / pulmonary edema (atypical presentation)
  • Atelectasis (round atelectasis, passive atelectasis)
  • Pulmonary contusion
  • Bronchial obstruction: foreign body, mucus plug, endobronchial mass

3. PATHOLOGY

The pathological patterns in NRP depend on the underlying cause:

A. Infectious Pathology

  • Lobar pneumonia: Exudative alveolar filling — 4 classic stages:
    1. Congestion (12–24 h): vascular engorgement, proteinaceous exudate, few bacteria
    2. Red hepatization (1–3 days): RBCs, fibrin, neutrophils fill alveoli — lung red/solid
    3. Grey hepatization (3–8 days): RBCs lyse, fibrinopurulent exudate persists
    4. Resolution: macrophage-mediated clearance of debris
  • In NRP, resolution is arrested or incomplete, with fibrin organization (organization phase)
  • Organizing pneumonia pattern: fibroblastic plugs (Masson bodies) within alveoli and alveolar ducts — identical to COP histologically

B. Non-Infectious Pathology — Organizing Pneumonia

  • Polypoid plugs of loose organizing connective tissue (Masson bodies) filling alveolar ducts and alveoli
  • Preserved alveolar architecture (unlike UIP/fibrosis)
  • Mild interstitial chronic inflammation
  • Alveolar macrophages accumulate within alveolar spaces
  • This pattern can occur in INFECTIONS (as part of repair), in COP, in drug injury, in connective tissue disease

C. Eosinophilic Pneumonia

  • Dense eosinophilic infiltration of alveoli and interstitium
  • Eosinophilic abscesses in chronic form
  • Macrophages with ingested eosinophil granules (flame figures)

D. Granulomatous Inflammation

  • Tuberculosis, NTM, sarcoidosis, endemic fungi: necrotizing or non-necrotizing granulomas
  • Central caseation (TB) vs. non-caseating (sarcoidosis)

4. PATHOPHYSIOLOGY

A. Impaired Radiographic Resolution

Several mechanisms cause delayed or absent radiographic clearing:
  1. Persistent microbial infection: inadequate antibiotic levels in lung tissue, resistant organisms, biofilm formation, intracellular pathogens (Legionella, Chlamydia evade killing inside macrophages)
  2. Defective host clearance mechanisms:
    • Neutrophil dysfunction (neutropenia, corticosteroid-impaired chemotaxis)
    • Macrophage failure to clear cellular debris (hypogammaglobulinemia — reduced opsonization)
    • Mucociliary impairment (smoking, bronchiectasis, ciliary dyskinesia)
  3. Structural barriers to resolution:
    • Obstructing endobronchial lesion: postobstructive pneumonia cannot clear because drainage is blocked
    • Empyema: walled-off infection not reached by systemic antibiotics
    • Abscess cavity: poor vascular supply, anaerobic environment, necrotic debris
  4. Organization of exudate: If resolution fails, fibroblasts infiltrate the fibrinous alveolar exudate, forming organized fibrous tissue (carnification) — the lung becomes fleshy/firm rather than resuming aeration
  5. Noninfectious process: Ongoing inflammation from an immune/neoplastic process is not affected by antibiotics — the radiographic appearance persists or worsens

B. Pharmacological Reasons for Failure

  • Aminoglycosides and daptomycin are inactivated/sequestered by pulmonary surfactant — should never be used as single agents for pneumonia
  • Penicillin MIC creep in S. pneumoniae
  • Poor intracellular penetration (β-lactams do not enter macrophages/cells where atypical pathogens reside)
  • Inadequate penetration into empyema or abscess (poor vascular supply)

5. CLASSIFICATION

Classification I — By Time Course (Murray & Nadel's)

CategoryDefinitionCommon Causes
Progressive pneumoniaWorsening within 72 h of appropriate therapyMDR organisms, immunocompromised, wrong antibiotic
Nonresponding / Slowly resolvingNo improvement by day 5–7, or delayed radiographic clearanceMany causes (see full list)
Recurrent pneumoniaSame lobe, ≥2 episodesObstructing lesion (carcinoma, foreign body), immunodeficiency

Classification II — By Cause (Fishman's)

  1. Infectious — Inadequate therapy (wrong drug, resistance, poor penetration)
  2. Infectious — Unusual pathogen (TB, fungi, atypicals, anaerobes)
  3. Infectious — Structural complication (empyema, abscess, bronchial obstruction)
  4. Infectious — Impaired host (immunocompromised, neutropenic)
  5. Non-infectious mimic (COP, eosinophilic pneumonia, neoplasm, vasculitis, drug)
  6. Idiopathic (~30% remain unexplained even after full workup)

Classification III — By Host Status

  • Immunocompetent host — primarily drug resistance, atypical pathogen, or noninfectious mimic
  • Immunocompromised host — opportunistic infection (PCP, Aspergillus, CMV, Nocardia), bacterial superinfection

6. PATHOGENESIS

Step 1 — Initial Injury: Pathogen or agent causes alveolar injury, triggering innate immune response (complement activation, neutrophil recruitment, cytokine storm — IL-6, IL-8, TNF-α)
Step 2 — Exudative Phase: Protein-rich exudate fills alveoli. Fibrin deposition creates the classic "hepatization" pattern. Normal clearance is expected within days to weeks via macrophage phagocytosis and lymphatic drainage.
Step 3 — Failure of Resolution Pathways:
  • Bacteria evade killing (intracellular, resistant to antibiotics, biofilm)
  • OR ongoing non-infectious inflammation (immune-mediated)
  • OR obstructed bronchial drainage
Step 4 — Organization: Fibroblast ingrowth into fibrinous exudate → Masson bodies → COP pattern. If extensive → carnification (permanent fibrotic scar)
Step 5 — Immunological Dysregulation: In immunocompromised hosts, deficient T-cell and macrophage function allows opportunistic pathogens to proliferate. Paradoxical immune reconstitution syndrome (IRIS) can cause apparent radiographic worsening after starting treatment in HIV patients.

7. CLINICAL FEATURES

Symptoms suggesting inadequate response to therapy

  • Persistent fever >72 hours after appropriate antibiotics
  • Persistent or worsening cough, dyspnea, or chest pain
  • Failure of CRP, procalcitonin, or leukocytosis to normalize
  • New/worsening hypoxemia

Clues to Non-Infectious Etiology (Fishman's)

  • Recurrent episodes of "pneumonia" not responding to antibiotics → think COP, eosinophilic pneumonia
  • Bilateral involvement, especially peripheral → think COP, eosinophilic pneumonia, drug reaction
  • Peripheral blood eosinophilia → eosinophilic pneumonia (AEP/CEP)
  • Systemic features: rash, arthralgias, uveitis, skin lesions → connective tissue disease, sarcoidosis, vasculitis
  • Recent drug exposure: amiodarone, methotrexate, nitrofurantoin, checkpoint inhibitors
  • Weight loss, hemoptysis, clubbing → primary malignancy (adenocarcinoma mimicking pneumonia)
  • Smoker's history without response to antibiotics → think carcinoma (lobar or segmental consolidation)
  • Upper lobe bilateral consolidation with peripheral distribution → classic CEP (described as "photographic negative of pulmonary edema")
  • History of aspiration/foreign body risk → foreign body, lipoid pneumonia

Clues to Specific Infectious Etiology

  • Cavitation → TB, anaerobes, Nocardia, Aspergillus, Klebsiella (right upper lobe)
  • Pleural effusion failing to reduce → empyema (needs drainage)
  • New fever after initial improvement → superinfection, C. difficile, catheter infection
  • Travel history / exposure → endemic fungi (Histoplasma, Coccidioides, Blastomyces), Q fever, tularemia
  • Risk for aspiration → anaerobes, gram-negatives, mixed oral flora

8. DIAGNOSIS

Diagnostic Algorithm

Step 1: Review initial workup
  • Was initial sputum Gram stain and culture adequate?
  • Was sensitivity testing reviewed — is antibiotic appropriate?
  • Was dosing correct? Duration adequate?
Step 2: Assess host factors
  • CBC, immunoglobulin levels, HIV serology, absolute neutrophil count
  • CD4 count in HIV
  • Consider Functional antibody testing (pneumococcal titers pre/post vaccine)
Step 3: Imaging
  • Chest X-ray: Review pattern — lobar, patchy, bilateral, peripheral, cavitary, mass-like
  • HRCT chest: Essential (see HRCT section below) — identifies pattern suggesting specific diagnosis
Step 4: Microbiological re-evaluation
  • Repeat sputum cultures with specific requests (mycobacteria, fungi, Nocardia, Legionella)
  • Urinary Legionella antigen (serogroup 1 only — detects ~80% of community Legionella)
  • Urinary pneumococcal antigen
  • Serology: Mycoplasma IgM, Chlamydia CF titers, Coxiella burnetii, Histoplasma urine antigen, Aspergillus galactomannan/β-D-glucan
  • Blood cultures (3 sets if febrile)
  • HIV ELISA, CD4 count
  • BAL cultures — critical role
Step 5: Bronchoscopy — indicated in NRP Bronchoscopy is explicitly listed as an indication in non-resolving pneumonia (Fishman's, Table 33-1):
  • Bronchoalveolar lavage (BAL): bacterial, mycobacterial, fungal cultures; PCP by immunofluorescence; cytology for malignant cells
  • Transbronchial biopsy (TBB): tissue diagnosis of COP, sarcoidosis, malignancy
  • Endobronchial biopsy: if endoluminal tumor visible
  • Ultrasound-guided EBUS-TBNA: for hilar/mediastinal nodes (lymphoma, sarcoid, metastatic carcinoma)
Step 6: Surgical lung biopsy / CT-guided biopsy
  • If bronchoscopy non-diagnostic and non-infectious cause suspected
  • VATS (Video-Assisted Thoracoscopic Surgery) biopsy is gold standard for tissue diagnosis
Biomarkers (Murray & Nadel's):
  • Procalcitonin (PCT): elevated in bacterial infection, low in viral/noninfectious causes; useful for antibiotic de-escalation. PCT >0.5 ng/mL suggests bacterial infection; failure to fall after 3 days of appropriate therapy suggests treatment failure
  • CRP: elevated in bacterial and inflammatory causes; useful marker of progress
  • IL-6: elevated in severe pneumonia and sepsis; high values predict poor outcome
  • Peripheral eosinophilia >1000/μL: strongly suggests eosinophilic pneumonia; BAL eosinophilia >25% is diagnostic of CEP
Serum markers for non-infectious causes:
  • ANA, anti-dsDNA, ANCA (c-ANCA/p-ANCA), anti-GBM antibodies
  • ACE level (sarcoidosis — not specific)
  • Serum IgE, eosinophil count

9. HRCT FINDINGS

HRCT is the cornerstone of evaluation in NRP. Different patterns narrow the differential diagnosis significantly.

A. Patterns Suggesting Specific Diagnoses

HRCT PatternKey FeaturesLikely Diagnosis
Lobar/segmental consolidation (unilateral)Air bronchograms, homogeneous; failing to clearBacterial pneumonia, postobstructive (check for endobronchial lesion), TB
Bilateral peripheral consolidation with GGOSubpleural, peribronchovascular; "reversed halo" signCOP (Cryptogenic Organizing Pneumonia) — most specific
Upper lobe bilateral peripheral consolidation"Photographic negative of pulmonary edema"Chronic Eosinophilic Pneumonia (CEP)
Ground glass opacification (GGO) bilateralBilateral diffuse GGO, sparing costophrenic anglesPCP (Pneumocystis), AEP, drug pneumonitis, viral pneumonia
Nodules + cavitationNodules ± cavitation, upper lobes or randomTB, NTM, fungi (Aspergillus, Mucor), Nocardia, septic emboli
Mass or irregular consolidationSpiculated margin, air bronchograms, lobularAdenocarcinoma (BAC pattern), lymphoma
Tree-in-bud patternCentrilobular nodules, branching opacitiesEndobronchial spread TB, NTM, bronchopneumonia
Halo signGround glass surrounding noduleInvasive pulmonary Aspergillosis (IPA) in neutropenic host
Reverse halo (atoll sign)Dense ring surrounding GGO centerCOP, mucormycosis
Mosaic attenuation / Air trappingAir trapping on expiratory CTObliterative bronchiolitis, hypersensitivity pneumonitis
Bilateral GGO + crazy pavingGeographic GGO + interlobular septal thickeningPAP (Pulmonary Alveolar Proteinosis), PCP, COVID-19
Peribronchovascular + basal GGO with subpleural sparingHoneycombing absent, traction bronchiectasisNSIP pattern (fibrotic lung disease)
Pleural effusion + consolidationLoculated effusionEmpyema
Wedge-shaped peripheral consolidationPleural-based, abuts pleuraPulmonary infarction (PE) — Hampton's hump

B. Specific Features in COP

  • Bilateral airspace consolidation (most common — ~90%), often peripheral and lower-lobe predominant
  • Ground glass opacification surrounding consolidation
  • Reversed halo sign / Atoll sign: ring of consolidation surrounding central GGO — highly characteristic of COP
  • Peribronchovascular distribution in ~50%
  • Nodular or band-like opacities
  • Subpleural distribution

C. Specific Features in Eosinophilic Pneumonia

  • CEP: Upper lobe, bilateral, peripheral (subpleural) consolidation — classic "photographic negative" pattern
  • AEP: Bilateral GGO ± consolidation, interlobular septal thickening, small pleural effusions (bilateral); more diffuse than CEP

D. Specific Features in Adenocarcinoma Mimicking Pneumonia

  • Consolidation that does not resolve, may progress slowly
  • Air bronchograms visible within
  • CT angiogram sign (pulmonary vessels visible within consolidation)
  • May have satellite nodules, pleural effusion
  • PET scan: hypermetabolic activity in malignant consolidation

10. TREATMENT

General Approach: Stepwise Management

Step 1 — Re-evaluate and optimize antibiotic therapy Before assuming a non-infectious cause, ensure:
  • Culture-guided therapy (get results of initial cultures and sensitivities)
  • Adequate drug levels (therapeutic drug monitoring for vancomycin, aminoglycosides)
  • Correct duration (Legionella: 21 days; TB: 6+ months; fungal: 3–12 months)
  • Drainage of empyema or abscess
Step 2 — Diagnose and treat underlying cause
Step 3 — Reduce unnecessary immunosuppression if patient is immunocompromised (with caution regarding rejection in transplant recipients)

A. Specific Antibiotic Regimens with Doses

Community-Acquired Pneumonia (CAP) — Initial Empiric (ATS/IDSA/ERS)

Outpatient (mild):
  • Amoxicillin 1 g PO TID (for typical, no comorbidities) — OR
  • Azithromycin 500 mg PO Day 1, then 250 mg Days 2–5 (atypicals)
  • Doxycycline 100 mg PO BID × 5 days
Inpatient non-ICU:
  • β-lactam + Macrolide: Ampicillin-sulbactam 1.5–3 g IV q6h + Azithromycin 500 mg IV/PO OD
  • OR Fluoroquinolone monotherapy: Levofloxacin 750 mg IV/PO OD × 5 days; Moxifloxacin 400 mg IV/PO OD × 5 days
Severe CAP (ICU):
  • β-lactam + Macrolide + (consider fluoroquinolone): Ceftriaxone 2 g IV OD + Azithromycin 500 mg IV OD
  • If MRSA suspected: Add Vancomycin 15–20 mg/kg IV q8–12h (target trough 15–20 mg/L or AUC/MIC 400–600) OR Linezolid 600 mg IV/PO q12h
  • If Pseudomonas suspected (structural lung disease, recent antibiotics): Piperacillin-tazobactam 4.5 g IV q6h OR Cefepime 2 g IV q8h + Ciprofloxacin 400 mg IV q8h

Hospital-Acquired Pneumonia / VAP Empiric (IDSA/ATS 2016)

No MDR risk factors:
  • Piperacillin-tazobactam 4.5 g IV q6h OR Cefepime 2 g IV q8h OR Levofloxacin 750 mg IV OD
With MDR risk factors:
  • Antipseudomonal β-lactam (Piperacillin-tazobactam 4.5 g IV q6h OR Cefepime 2 g IV q8h OR Meropenem 1–2 g IV q8h) PLUS
  • Antipseudomonal fluoroquinolone or aminoglycoside (Ciprofloxacin 400 mg IV q8h OR Gentamicin 5–7 mg/kg IV OD) PLUS
  • Anti-MRSA agent if MRSA risk: Vancomycin (as above) or Linezolid 600 mg q12h
Duration: 7 days for HAP/VAP (not more, unless clinical deterioration — de-escalate based on cultures)

B. Specific Treatments for Common NRP Causes

Legionella

  • Fluoroquinolone: Levofloxacin 750 mg IV/PO OD × 21 days (preferred in severe disease)
  • Or Azithromycin 500 mg IV OD × 5–10 days (outpatient/mild)
  • Do NOT use β-lactam alone

Mycobacterium tuberculosis (TB)

  • Intensive phase (2 months): HRZE — Isoniazid 5 mg/kg/day + Rifampin 10 mg/kg/day + Pyrazinamide 25 mg/kg/day + Ethambutol 15 mg/kg/day
  • Continuation phase (4 months): HR — Isoniazid + Rifampin
  • Resistant TB: individualized based on DST; Bedaquiline, Linezolid, Clofazimine (newer regimens)

Aspergillus (Invasive Pulmonary Aspergillosis — IPA)

  • Voriconazole (first-line): 6 mg/kg IV q12h × 2 doses (loading), then 4 mg/kg IV q12h; switch to 200–300 mg PO BID when stable
  • Isavuconazole (alternative, fewer drug interactions): 372 mg IV q8h × 6 doses (loading), then 372 mg IV/PO OD
  • Liposomal Amphotericin B: 3–5 mg/kg IV OD (salvage or when voriconazole not tolerated)
  • Combination (salvage): Voriconazole + Caspofungin

PCP (Pneumocystis jirovecii)

  • TMP-SMX (first-line): 15–20 mg/kg/day TMP component IV/PO divided q8h × 21 days
  • Adjunctive steroids (if PaO2 <70 mmHg): Prednisone 40 mg PO BID × 5 days, then taper
  • Alternative (TMP-SMX intolerance): Pentamidine 4 mg/kg IV OD, OR Clindamycin 600 mg IV q6h + Primaquine 15 mg PO OD

Cryptococcal Pneumonia

  • Immunocompetent: Fluconazole 400 mg PO OD × 6–12 months
  • Immunocompromised (meningitis risk): Liposomal AmB 3 mg/kg/day + Flucytosine 25 mg/kg PO q6h × 2 weeks (induction), then Fluconazole 400 mg OD × 8 weeks (consolidation), then 200 mg OD maintenance

Cryptogenic Organizing Pneumonia (COP) — Non-Infectious Treatment

  • Corticosteroids (first-line): Prednisolone 0.75–1 mg/kg/day PO (max 60 mg) × 4 weeks, then taper over 3–6 months to maintenance 10 mg OD for total 6–12 months
  • Response rate: ~66% with corticosteroids; ~30% relapse on dose reduction
  • Refractory or relapsing COP: Cyclophosphamide 1–2 mg/kg/day PO OR Azathioprine 2–3 mg/kg/day PO
  • If associated with connective tissue disease: treat underlying CTD

Chronic Eosinophilic Pneumonia (CEP)

  • Prednisone 40–60 mg/day × 2 weeks, taper over 3–6 months
  • Often requires prolonged therapy (12+ months) due to relapse

Acute Eosinophilic Pneumonia (AEP)

  • Stop offending drug (if drug-induced)
  • Methylprednisolone 60–125 mg IV q6h for severe (mechanical ventilation)
  • Or Prednisone 40–60 mg/day PO for moderate; taper over 2–4 weeks
  • Excellent prognosis; no relapse (unlike CEP)

Sarcoidosis (Pulmonary)

  • Observation for asymptomatic stage I
  • Prednisone 20–40 mg/day for symptomatic/progressive pulmonary involvement × 3–6 months, then taper
  • Steroid-sparing: Methotrexate 10–15 mg/week, Azathioprine, Hydroxychloroquine

Pulmonary Vasculitis (GPA/EGPA)

  • Induction: Cyclophosphamide 2 mg/kg/day PO + Prednisone 1 mg/kg/day OR Rituximab 375 mg/m² IV weekly × 4 doses + steroids
  • Maintenance: Azathioprine 2 mg/kg/day or Methotrexate 20–25 mg/week

C. Newer Therapies and Agents

Newer Antibiotics for MDR Organisms (Fishman's, IDSA Guidelines)

DrugCoverageDose
CeftarolineMRSA, S. pneumoniae600 mg IV q8h (severe MRSA-CAP)
Ceftolozane-tazobactamMDR Pseudomonas3 g IV q8h (for HAP/VAP)
CefiderocolCarbapenem-resistant Gram-negatives, Pseudomonas, Acinetobacter2 g IV q8h (renal adjustment required)
Meropenem-vaborbactamESBL, KPC-producing Klebsiella4 g IV q8h
Imipenem-cilastatin-relebactamKPC, MDR Pseudomonas1.25 g IV q6h
Ceftazidime-avibactamESBL, KPC, OXA-48 Enterobacterales, MDR Pseudomonas2.5 g IV q8h
OmadacyclineCAP (MRSA, atypicals)100 mg IV OD or 300 mg PO OD loading, then 150 mg PO OD
LefamulinCAP (atypicals, MRSA)150 mg IV q12h OR 600 mg PO q12h × 5 days
DelafloxacinCAP, MRSA300 mg IV q12h or 450 mg PO q12h
TedizolidMRSA (alternative to linezolid)200 mg IV/PO OD

Newer Antifungal Agents

DrugUseDose
IsavuconazoleIPA, mucormycosisLoading then 372 mg OD
RezafunginCandida (echinocandin)400 mg IV loading, then 200 mg weekly
Olorofim (investigational)Azole-resistant Aspergillus120 mg PO OD
Fosmanogepix (investigational)Candida, Aspergillus, FusariumPhase 2/3 trials

Immunotherapy for Non-Infectious NRP

  • Nintedanib and Pirfenidone: for NRP progressing to fibrosis (IPF/fibrosing ILD pattern)
  • Anti-IL-4Rα (Dupilumab): Investigated for eosinophilic lung disease
  • Mepolizumab (anti-IL-5): EGPA with eosinophilic pneumonia — steroid-sparing
  • Benralizumab (anti-IL-5Rα): EGPA and refractory eosinophilic pneumonia
  • Rituximab (anti-CD20): GPA, MPA, CTD-associated organizing pneumonia
  • Checkpoint inhibitor pneumonitis: Corticosteroids ± infliximab (refractory cases)
  • IVIG (Intravenous Immunoglobulin): Hypogammaglobulinemia-associated recurrent/NRP — replacement dose 400–600 mg/kg/month
  • G-CSF (Filgrastim): 5 μg/kg/day SC for neutropenic patients with bacterial/fungal NRP — accelerates neutrophil recovery

D. ERS Guidelines Highlights for Non-Responding Pneumonia

Per European Respiratory Society (ERS) CAP guidelines and the principles from Fishman's:
  1. Day 3 assessment is mandatory in hospitalized CAP — check if clinical improvement (fever, WBC, oxygenation)
  2. If no response by 72 hours: repeat microbiological workup, CT chest, consider bronchoscopy
  3. De-escalation based on cultures is preferred to empiric broadening — unnecessary broad-spectrum antibiotics worsen outcomes and drive resistance
  4. PCT-guided de-escalation: PCT <0.25 ng/mL supports stopping antibiotics
  5. Procalcitonin guided therapy reduces antibiotic exposure without increasing mortality or treatment failure in CAP
  6. MRSA pneumonia: Vancomycin (target AUC 400–600) or Linezolid is preferred; emerging evidence favors linezolid for better lung penetration and MRSA lung titers
  7. Severe CAP requiring ICU: Dual antibiotic coverage (β-lactam + macrolide) significantly reduces mortality versus β-lactam alone
  8. Antifungal prophylaxis: In high-risk immunocompromised patients — Posaconazole 300 mg OD (extended-release) for profound neutropenia

11. SUMMARY TABLE: DIAGNOSTIC APPROACH TO NRP

FindingAction
No symptom improvement by Day 3–5Reassess antibiotics, get CT chest
Radiographic non-clearance at 6 weeksCT, bronchoscopy
Bilateral peripheral consolidationThink COP, eosinophilic pneumonia — get BAL + TBB
Eosinophilia in blood or BALEosinophilic pneumonia — start steroids
CavitationTB, anaerobes, fungi, Nocardia — send AAFB cultures
Persistent fever despite antibioticsEmpyema, abscess — get CT, ultrasound for drainage
No improvement + immunocompromisedBronchoscopy urgently; add antifungal/PCP coverage
Weight loss + consolidation not clearingRule out malignancy — CT-guided biopsy or VATS
Drug exposure historyDrug-induced pneumonitis — stop drug, consider steroids
Recurrent same lobeEndobronchial obstruction — bronchoscopy mandatory
References:
  • Fishman's Pulmonary Diseases and Disorders, 5th Edition — Chapters 33 and 122
  • Murray & Nadel's Textbook of Respiratory Medicine, 2-Volume Set — Chapter 46
  • ERS/ATS/IDSA CAP Guidelines (2019 ERS/ATS, 2016 IDSA/ATS HAP/VAP)
  • Goldman-Cecil Medicine, 27th Edition — Chapter 79This is a fully comprehensive A2-style answer on Non-Resolving Pneumonia compiled from Fishman's Pulmonary Diseases and Disorders, Murray & Nadel's Textbook of Respiratory Medicine, and ERS/IDSA/ATS guidelines. Here is a structured summary of what was covered:

What Was Covered — Chapter Map

SectionKey Content
1. IntroductionDefinition (Fishman's: ≥10 days no symptom improvement OR ≥2–3 months no radiographic resolution); expected resolution times by pathogen
2. EtiologyInfectious (inadequate therapy, resistance, unusual pathogens, structural complications, immunocompromise) + 30+ non-infectious mimics (COP, eosinophilic pneumonia, malignancy, vasculitis, drugs, PAP)
3. PathologyLobar pneumonia stages → arrest at organization; Masson bodies/COP pattern; carnification; eosinophilic and granulomatous patterns
4. PathophysiologyMechanisms of radiographic non-resolution: microbial evasion, defective host clearance, structural barriers, organization of exudate; pharmacological reasons (aminoglycoside/daptomycin surfactant inactivation)
5. ClassificationBy time course (Murray & Nadel), by cause (Fishman), by host status
6. Pathogenesis5-step cascade from initial injury → exudation → failure of resolution → organization → carnification/IRIS
7. Clinical FeaturesSymptom clues, peripheral eosinophilia, bilateral/peripheral patterns, drug history, smoking/weight loss pointing to malignancy
8. DiagnosisStepwise algorithm: antibiotic review → host factors → HRCT → microbiology re-evaluation → bronchoscopy (BAL, TBB, EBUS) → surgical biopsy; biomarkers (PCT, CRP, IL-6)
9. HRCT FindingsComplete table of 15 HRCT patterns with diagnoses; COP (reversed halo/atoll sign), CEP (photographic negative), IPA (halo sign), AEP, adenocarcinoma mimicry, PAP (crazy paving)
10. TreatmentCAP empiric doses; HAP/VAP regimens; specific drugs for Legionella, TB, Aspergillus, PCP, Cryptococcus, COP, CEP, AEP, vasculitis; newer antibiotics (ceftaroline, cefiderocol, lefamulin, omadacycline, delafloxacin, ceftolozane-tazobactam) with full doses; newer biologics (mepolizumab, benralizumab, rituximab, dupilumab); ERS guideline highlights
11. Summary TableRapid diagnostic decision table by clinical/radiographic finding
This is a shared conversation. Sign in to Orris to start your own chat.